U.S., May 1 -- ClinicalTrials.gov registry received information related to the study (NCT06950294) titled 'iNO300 Therapy in Critically Ill Patients With Pneumonia' on April 13.
Brief Summary: The goal of this clinical trial is to learn the formation and recovery rate of methemoglobin (MetHb) in severely sick patients with pneumonia who receive high doses of inhaled nitric oxide (iNO) therapy at 250 parts per million (ppm), not exceeding 300 ppm. Meanwhile, the benefits of the therapy to treat severely sick patients with pneumonia will be explored. Patients who are 18 years or older, newly diagnosed with pneumonia, and severely sick with requirement of a breathing machine could be included. The main questions it aims to answer are:
How do...